Dr. Xie’s PhD program at Zhejiang University focused on the molecular signaling regulation of innate immunity and identified two key membrane proteins, Siglec-g/10(Cell, 2013) and Rhbdd3 (Nature immunology, 2014). As a postdoctoral researcher at University of Oxford, he moved on to investigate the dynamic interaction between macrophage and lymphocytes in resident tissues and discovered that a novel B cell differentiation regulator, Zbtb18 (Journal of Immunology, 2021) acted as a potential cancer suppressor. Before joining LIDE, Dr. Xie was the Research Director for Shanghai X.B.H Biotech (GV20 oncotherapy), leading efforts to identify novel immuno-oncology targets for drug development.  With more than 10 years of experience in cellular and molecular immunology, he is now leading LIDE’s cancer research programs from basic science to clinical translation.